Clinical Trials Logo

Clinical Trial Details — Status: Active, not recruiting

Administrative data

NCT number NCT04100018
Other study ID # CA209-7DX
Secondary ID 2019-002030-36
Status Active, not recruiting
Phase Phase 3
First received
Last updated
Start date February 6, 2020
Est. completion date June 27, 2024

Study information

Verified date May 2024
Source Bristol-Myers Squibb
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to assess the safety and effectiveness of nivolumab with docetaxel in men with advanced castration resistant prostate cancer who have progressed after second-generation hormonal manipulation.


Recruitment information / eligibility

Status Active, not recruiting
Enrollment 1095
Est. completion date June 27, 2024
Est. primary completion date June 1, 2023
Accepts healthy volunteers No
Gender Male
Age group 18 Years and older
Eligibility Inclusion Criteria: - Histologic confirmation of adenocarcinoma of the prostate without small cell features - Current evidence of metastatic disease documented by either bone lesions on radionuclide bone scan and/or soft tissue lesions on computerized tomography/magnetic resonance imaging (CT/MRI) - Eastern Cooperative Oncology Group (ECOG) performance status 0-1 - Ongoing androgen deprivation therapy (ADT) with a gonadotropin-releasing hormone (GnRH) analogue or bilateral orchiectomy - Documented prostate cancer progression per Prostate Cancer Working Group (PCWG3) criteria within 6 months prior to screening - Chemotherapy-naïve for metastatic castration-resistant prostate cancer (mCRPC), with 1 to 2 prior second generation hormonal therapies in the recurrent non-metastatic setting and/or metastatic setting, and no more than 1 second generation hormonal therapy in the mCRPC setting. Must have progressed during or after second generation hormonal therapy or have documented intolerance to second generation hormonal therapy - Participants must meet one of the following criteria regarding tissue submission: Sufficient tumor samples from a newly obtained ("fresh") biopsy (obtained during screening); or archival tumor tissue in the form of formalin-fixed paraffin-embedded (FFPE) block or unstained tumor tissue slides. For participants with bone-only disease or inaccessible soft tissue lesions or if the biopsy procedure would pose an unacceptable clinical risk for the participant, submission of tumor tissue obtained from a fresh biopsy is not required. - Men must agree to follow specific methods of contraception, if applicable Exclusion Criteria: - Active brain metastases - Active, known, or suspected autoimmune disease - Condition requiring systemic treatment with corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of start of study treatment. Inhaled or topical steroids or adrenal replacement steroid doses are permitted in the absence of active autoimmune disease - Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 antibody, or any other antibody or drug specifically targeting T-cell co-stimulation or checkpoint pathways - Prior treatment with docetaxel or other chemotherapy for mCRPC. Prior docetaxel for metastatic castration-sensitive prostate cancer is permitted if at least 12 months have elapsed from last dose of docetaxel Other protocol-defined inclusion/exclusion criteria apply

Study Design


Related Conditions & MeSH terms


Intervention

Biological:
Nivolumab
Specified dose on specified days
Drug:
Prednisone
Specified dose on specified days
Docetaxel
Specified dose on specified days
Other:
Placebo
Specified dose on specified days

Locations

Country Name City State
Argentina Local Institution - 0077 Buenos Aires
Argentina Local Institution - 0178 Buenos Aires
Argentina Local Institution - 0185 Buenos Aires
Argentina Local Institution - 0369 La Rioja
Argentina Local Institution - 0129 Mar del Plata Buenos Aires
Argentina Local Institution - 0153 Parana Cordoba
Argentina Local Institution - 0061 Pergamino Buenos Aires
Argentina Local Institution - 0393 Rio Cuarto Cordoba
Argentina Local Institution - 0394 San Juan
Argentina Local Institution - 0083 Viedma RIO Negro
Australia Local Institution - 0379 Ballarat Victoria
Australia Local Institution - 0040 Frankston Victoria
Australia Local Institution - 0152 Gosford New South Wales
Australia Local Institution - 0091 Lismore New South Wales
Australia Local Institution - 0032 Malvern Victoria
Australia Local Institution - 0010 North Adelaide South Australia
Australia Local Institution - 0006 South Brisbane Queensland
Australia Local Institution - 0132 Wahroonga New South Wales
Australia Local Institution - 0127 Westmead New South Wales
Australia Local Institution - 0084 Woolloongabba Queensland
Austria Local Institution - 0118 Linz Upper Austria
Austria Local Institution - 0038 Salzburg
Austria Local Institution - 0131 Wien
Austria Local Institution - 0157 Wien
Belgium Local Institution - 0122 Anderlecht Brussel
Belgium Local Institution - 0121 Brugge
Belgium Local Institution - 0114 Gent
Belgium Local Institution - 0162 Gent
Belgium Local Institution - 0137 Turnhout
Belgium Local Institution - 0029 Wilrijk
Brazil Local Institution - 0022 Belo Horizonte Minas Gerais
Brazil Local Institution - 0097 Belo Horizonte Minas Gerais
Brazil Local Institution - 0086 Campinas SAO Paulo
Brazil Local Institution - 0082 Curitiba Parana
Brazil Local Institution - 0100 Curitiba Parana
Brazil Local Institution - 0058 Ijui Rio Grande Do Sul
Brazil Local Institution - 0321 Natal Rio Grande Do Norte
Brazil Local Institution - 0056 Porto Alegre RIO Grande DO SUL
Brazil Local Institution - 0057 Porto Alegre Rio Grande Do Sul
Brazil Local Institution - 0063 Porto Alegre RS
Brazil Local Institution - 0060 Rio de Janeiro
Brazil Local Institution - 0189 Rio de Janeiro
Brazil Local Institution - 0059 Santo Andre SP
Brazil Local Institution - 0096 Sao Jose Do Rio Preto Sao Paulo
Brazil Local Institution - 0080 Sao Paulo
Brazil Local Institution - 0273 Sao Paulo
Brazil Local Institution - 0328 Sao Paulo
Canada Local Institution - 0151 Brampton Ontario
Canada Local Institution - 0143 Montreal Quebec
Canada Local Institution - 0191 Toronto Ontario
Chile Local Institution - 0378 Providencia Metropolitana
Chile Local Institution - 0026 Santiago RM
Chile Local Institution - 0025 Santiago de Chile Metropolitana
Chile Local Institution - 0377 Santiago de Chile Metropolitana
Chile Local Institution - 0027 Vina del Mar Valparaiso
China Local Institution - 0320 Baoding Shi Hebei
China Local Institution - 0245 Beijing Beijing
China Local Institution - 0254 Beijing Beijing
China Local Institution - 0312 Beijing Bei
China Local Institution - 0337 Beijing Beijing
China Local Institution - 0345 Beijing Beijing
China Local Institution - 0140 Beijing Shi Beijing
China Local Institution - 0168 Changsha Hunan
China Local Institution - 0253 Chengdu Sichuan
China Local Institution - 0256 Fuzhou Fujian
China Local Institution - 0319 Guangzhou Guangdong
China Local Institution - 0316 Hangzhou Zhejiang
China Local Institution - 0344 Hangzhou Zhejiang
China Local Institution - 0224 Harbin Shi Heilongjiang
China Local Institution - 0314 Henan Sheng Henan
China Local Institution - 0326 Jinan Shandong
China Local Institution - 0330 Nanchang Jiangxi
China Local Institution - 0347 Nanchang Jiangxi
China Local Institution - 0165 Nanjing Jiangsu
China Local Institution - 0317 Nanjing Jiangsu
China Local Institution - 0325 Nanjing Jiangsu
China Local Institution - 0155 Shanghai Shanghai
China Local Institution - 0161 Shenyang Liaoning
China Local Institution - 0310 Urumqi Xinjiang
China Local Institution - 0313 Wu Han Hubei
China Local Institution - 0353 Xian Shannxi
China Local Institution - 0275 Zhengzhou Henan
Czechia Local Institution - 0093 Brno
Czechia Local Institution - 0108 Brno
Czechia Local Institution - 0049 Olomouc
Czechia Local Institution - 0088 Ostrava
Czechia Local Institution - 0361 Prague
Czechia Local Institution - 0050 Praha
France Local Institution - 0107 Angers Cedex 02
France Local Institution - 0202 Brest
France Local Institution - 0398 Dijon
France Local Institution - 0030 Hyeres
France Local Institution - 0167 Le Mans Sarthe
France Local Institution - 0079 Lille Nord
France Local Institution - 0109 Montpellier
France Local Institution - 0395 Montpellier
France Local Institution - 0384 Nice cedex 2
France Local Institution - 0068 Nimes Cedex 9
France Local Institution - 0071 Paris
France Local Institution - 0106 Paris
France Local Institution - 0381 Paris
France Local Institution - 0133 Pierre-Benite
France Local Institution - 0399 Reims
France Local Institution - 0380 Rennes
France Local Institution - 0105 Strasbourg Alsace
France Local Institution - 0387 Strasbourg
France Local Institution - 0271 Villejuif Cedex
Germany Local Institution - 0089 Bonn
Germany Local Institution - 0090 Dresden Saxony
Germany Local Institution - 0376 Duesseldorf
Germany Local Institution - 0172 Emmendingen
Germany Local Institution - 0142 Erlangen
Germany Local Institution - 0018 Frankfurt am Main
Germany Local Institution - 0064 Hamburg
Germany Local Institution - 0069 Hamburg
Germany Local Institution - 0389 Heidelberg
Germany Local Institution - 0014 Koblenz Rheinland Pfa
Germany Local Institution - 0004 Magdeburg
Germany Local Institution - 0372 Marburg
Germany Local Institution - 0204 Muenchen
Germany Local Institution - 0036 Muenster
Germany Local Institution - 0023 Nuertingen Baden-Wuerttemberg
Germany Local Institution - 0169 Tuebingen
Hong Kong Local Institution - 0045 Hong Kong
Hong Kong Local Institution - 0145 Hong Kong
Hong Kong Local Institution - 0146 Hong Kong
Israel Local Institution - 0072 Haifa
Israel Local Institution - 0388 Jerusalem
Israel Local Institution - 0368 Kfar Saba
Israel Local Institution - 0128 Petach tikva
Israel Local Institution - 0135 Ramat Gan
Israel Local Institution - 0138 Tel Aviv
Italy Local Institution - 0099 Benevento
Italy Local Institution - 0001 Bergamo
Italy Local Institution - 0111 Bologna
Italy Local Institution - 0039 Brescia
Italy Local Institution - 0053 Cremona
Italy Local Institution - 0066 Milan
Italy Local Institution - 0120 Napoli
Italy Local Institution - 0070 Orbassano
Italy Local Institution - 0037 Parma
Italy Local Institution - 0199 Pisa
Italy Local Institution - 0046 Rome
Italy Local Institution - 0385 Rome
Italy Local Institution - 0067 Trento
Japan Local Institution - 0340 Akita-shi Akita
Japan Local Institution - 0346 Chiba-shi Chiba
Japan Local Institution - 0280 Fukuoka-shi Fukuoka
Japan Local Institution - 0309 Hamamatsu Shizuoka
Japan Local Institution - 0358 Hirosaki-shi Aomori
Japan Local Institution - 0342 Kamigyo-ku Kyoto
Japan Local Institution - 0355 Kashihara-shi Nara
Japan Local Institution - 0324 Kumamoto-Shi Kumamoto
Japan Local Institution - 0307 Matsuyama-shi Ehime
Japan Local Institution - 0341 Nagasaki
Japan Local Institution - 0362 Nagoya-shi Aichi
Japan Local Institution - 0327 Niigata
Japan Local Institution - 0354 Okayama
Japan Local Institution - 0338 Osaka
Japan Local Institution - 0323 Osaka Sayama Osaka
Japan Local Institution - 0343 Osaka shi Osaka
Japan Local Institution - 0339 Sakura-Shi Chiba
Japan Local Institution - 0281 Sapporo Hokkaido
Japan Local Institution - 0296 Sapporo-shi Hokkaido
Japan Local Institution - 0308 Tokyo
Japan Local Institution - 0279 Toyama-shi Toyama
Japan Local Institution - 0282 Ube shi Yamaguchi
Japan Local Institution - 0278 Wakayama
Japan Local Institution - 0283 Yokohama-shi Kanagawa
Korea, Republic of Local Institution - 0391 Daegu
Korea, Republic of Local Institution - 0298 Incheon
Korea, Republic of Local Institution - 0375 Jeollanam-do
Korea, Republic of Local Institution - 0297 Jung-gu Daejeon
Korea, Republic of Local Institution - 0374 Seodaemun-Gu
Korea, Republic of Local Institution - 0171 Seoul
Korea, Republic of Local Institution - 0187 Seoul
Korea, Republic of Local Institution - 0193 Seoul
Korea, Republic of Local Institution - 0370 Seoul
Korea, Republic of Local Institution - 0373 Seoul
Korea, Republic of Local Institution - 0186 Songnam-si Gyeonggi-do
Korea, Republic of Local Institution - 0158 Yangsan Si
Mexico Local Institution - 0017 Mexico City D.f.
Mexico Local Institution - 0062 Morelia Michoacan
Mexico Local Institution - 0015 Zapopan Jalisco
Mexico Local Institution - 0016 Zapopan Jalisco
New Zealand Local Institution - 0101 Hamilton
New Zealand Local Institution - 0184 Palmerston North Manawatu-Wanganui
New Zealand Local Institution - 0102 Tauranga
Poland Local Institution - 0383 Bydgoszcz
Poland Local Institution - 0136 Koszalin
Poland Local Institution - 0009 Lodz
Poland Local Institution - 0013 Lublin
Poland Local Institution - 0065 Poznan
Poland Local Institution Warsaw
Poland Local Institution - 0095 Warszawa
Puerto Rico Local Institution - 0329 Rio Piedras
Puerto Rico Local Institution - 0359 San Juan
Romania Local Institution - 0042 Bucharest
Romania Local Institution - 0041 Cluj Cluj-Napoca
Romania Local Institution - 0043 Cluj Napoca
Romania Local Institution - 0020 Constanta
Romania Local Institution - 0052 Craiova
Romania Local Institution - 0035 Timisoara
Russian Federation SBHI Arkhangelsk Region - Arkhangelsk Clinical Oncological Dispensary Arkhangelsk
Russian Federation SAHI Republican Clinical Oncology Dispensary of MoH of RT Kazan
Russian Federation Clinical Hospital MEDSI in Otradnoye Krasnogorsk Moscow Region
Russian Federation Federal State Budgetary Institution N.N. Blokhin National Medical Research Center of Oncology of the Moscow
Russian Federation P.A. Herzen Moscow Oncology Research Institute Moscow
Russian Federation Sechenov University Moscow
Russian Federation FSBI National Medical Research Radiology Center NMRRC - A. Tsyb Medical Radiological Research Centre Obninsk
Russian Federation Budgetary Healthcare Institution of Omsk Region &quot,Clinical Oncological Dispensary&quot, Omsk
Russian Federation Andros Clinic LLC Saint-Petersburg
Russian Federation Russian Scientific Centre of Radiology and Surgical Technologies n.a. acad. M.A. Saint-Petersburg
Singapore Local Institution - 0005 Singapore
Singapore Local Institution - 0116 Singapore
Singapore Local Institution - 0170 Singapore
Spain Local Institution - 0073 Barcelona
Spain Local Institution - 0123 Barcelona
Spain Local Institution - 0360 Cordoba
Spain Local Institution - 0044 Girona
Spain Local Institution - 0034 Lugo
Spain Local Institution - 0003 Madrid
Spain Local Institution - 0024 Madrid
Spain Local Institution - 0031 Madrid
Spain Local Institution - 0076 Madrid
Spain Local Institution - 0364 Madrid
Spain Local Institution - 0141 Manresa Barcelona
Spain Local Institution - 0124 Sabadell (Barcelona)
Spain Local Institution - 0363 Sevilla
Taiwan Local Institution - 0192 Niaosng Kaohsiung
Taiwan Local Institution - 0194 Taichung
Taiwan Local Institution - 0371 Taichung
Taiwan Local Institution - 0386 Tainan
Taiwan Local Institution - 0175 Taipei
Taiwan Local Institution - 0188 Taipei
Turkey Local Institution - 0094 Adana
Turkey Local Institution - 0119 Ankara
Turkey Local Institution - 0130 Ankara
Turkey Local Institution - 0113 Istanbul
Turkey Local Institution - 0104 Izmir
Turkey Local Institution - 0112 Malatya
United Kingdom Local Institution - 0048 Guildford Surrey
United Kingdom Local Institution - 0154 London
United Kingdom Local Institution - 0173 London Greater London
United Kingdom Local Institution - 0098 Manchester Lancashire
United Kingdom Local Institution - 0008 Northwood Middlesex
United Kingdom Local Institution - 0051 Nottingham Nottinghamshire
United Kingdom Local Institution - 0265 Oxford Oxfordshire
United States Local Institution - 0300 Albany New York
United States Local Institution - 0180 Allentown Pennsylvania
United States Local Institution - 0012 Anchorage Alaska
United States Local Institution - 0117 Atlanta Georgia
United States Local Institution - 0286 Austin Texas
United States Local Institution - 0074 Bala-Cynwyd Pennsylvania
United States Local Institution - 0150 Baltimore Maryland
United States Local Institution - 0332 Brandywine Maryland
United States Local Institution - 0233 Charleston South Carolina
United States Local Institution - 0333 Columbus Ohio
United States Local Institution - 0303 Dallas Texas
United States Local Institution - 0087 Denver Colorado
United States Local Institution - 0365 East Brunswick New Jersey
United States Local Institution - 0139 Florham Park New Jersey
United States Local Institution - 0183 Fort Wayne Indiana
United States Local Institution - 0149 Germantown Tennessee
United States Local Institution - 0196 Hollywood Florida
United States Local Institution - 0195 Houston Texas
United States Local Institution - 0284 Houston Texas
United States Local Institution - 0397 Jacksonville Florida
United States Local Institution - 0269 Jonesboro Arkansas
United States Local Institution - 0164 Lakeland Florida
United States Local Institution - 0302 Louisville Kentucky
United States Local Institution - 0126 Marietta Georgia
United States Local Institution - 0305 Mobile Alabama
United States Local Institution - 0115 Myrtle Beach South Carolina
United States Local Institution - 0287 Niles Illinois
United States Local Institution - 0299 Omaha Nebraska
United States Local Institution - 0179 Orange California
United States Local Institution - 0181 Orlando Florida
United States Local Institution - 0285 Pensacola Florida
United States Local Institution - 0292 Pittsburgh Pennsylvania
United States Local Institution - 0028 Port Jefferson Station New York
United States Local Institution - 0055 Rancho Mirage California
United States Local Institution - 0260 Redondo Beach California
United States Local Institution - 0011 San Antonio Texas
United States Local Institution - 0081 Santa Monica California
United States Local Institution - 0110 Seattle Washington
United States Local Institution - 0289 Spokane Washington
United States Local Institution - 0382 Thomasville Georgia
United States Local Institution - 0293 Tucson Arizona
United States The University of Texas Health Science Center at Tyler DBA UT Health East Texas Hope Cancer Center Tyler Texas
United States Local Institution - 0366 Washington District of Columbia
United States Local Institution - 0190 West Haven Connecticut
United States Local Institution - 0177 Weston Florida

Sponsors (1)

Lead Sponsor Collaborator
Bristol-Myers Squibb

Countries where clinical trial is conducted

United States,  Argentina,  Australia,  Austria,  Belgium,  Brazil,  Canada,  Chile,  China,  Czechia,  France,  Germany,  Hong Kong,  Israel,  Italy,  Japan,  Korea, Republic of,  Mexico,  New Zealand,  Poland,  Puerto Rico,  Romania,  Russian Federation,  Singapore,  Spain,  Taiwan,  Turkey,  United Kingdom, 

Outcome

Type Measure Description Time frame Safety issue
Primary Radiographic progressive free survival (rPFS) assessed by Blinded Independent Central Review (BICR) per Prostate Cancer Working Group (PCWG3) Up to 530 rPFS events From the date of randomization to the first date of documented progression or death due to any cause, whichever occurs first, approximately 31 months
Primary Overall Survival (OS) From the date of randomization to the date of death from any cause, approximately 51 months. For participants who are alive, their survival time will be censored at the last date that they were known to be alive
Secondary Objective Response Rate (ORR) per PCWG3 From the date of randomization to the date of objectively documented progression or the date of subsequent systemic cancer therapy, whichever occurs first, approximately 31 months
Secondary Time to Response per PCWG3 (TTR-PCWG3) determined by BICR From the date of randomization to the date of the first documented complete response (CR) or partial response (PR), approximately 31 months
Secondary Duration of Response (DOR) per PCWG3 determined by BICR From the date of first response (CR/PR) to the date of first documented radiographic progression, or death due to any cause, approximately 31 months
Secondary Prostate-specific antigen (PSA) Response Rate (PSA-RR) Approximately 31 months
Secondary Time to PSA Progression (TTP-PSA) From date of randomization to the date of PSA progression per PCWG3, approximately 31 months
Secondary Incidence of Adverse Events (AEs) Approximately 31 months
Secondary Incidence of Serious Adverse Events (SAEs) Approximately 31 months
Secondary Incidence of AEs leading to discontinuation Approximately 31 months
Secondary Incidence of immune-mediated AEs Approximately 31 months
Secondary Incidence of deaths Approximately 31 months
Secondary Incidence of laboratory abnormalities: Clinical Chemistry Tests Approximately 31 months
Secondary Incidence of laboratory abnormalities: Hematology tests Approximately 31 months
Secondary Incidence of laboratory abnormalities: Serology tests Approximately 31 months
Secondary Median time to pain progression assessed by Brief Pain Inventory-Short Form (BPI-SF) Approximately 31 months
Secondary Incidence of changes from baseline in Physical Exam Approximately 31 months
Secondary Incidence of changes from baseline in vital signs: Respiratory rate Approximately 31 months
Secondary Incidence of changes from baseline in vital signs: Body temperature Approximately 31 months
Secondary Incidence of changes from baseline in vital signs: Blood pressure Approximately 31 months
Secondary Incidence of changes from baseline in vital signs: Heart Rate Approximately 31 months
Secondary Incidence of changes from baseline electrocardiogram (ECG) Approximately 31 months
See also
  Status Clinical Trial Phase
Recruiting NCT05540392 - An Acupuncture Study for Prostate Cancer Survivors With Urinary Issues Phase 1/Phase 2
Recruiting NCT05613023 - A Trial of 5 Fraction Prostate SBRT Versus 5 Fraction Prostate and Pelvic Nodal SBRT Phase 3
Recruiting NCT05156424 - A Comparison of Aerobic and Resistance Exercise to Counteract Treatment Side Effects in Men With Prostate Cancer Phase 1/Phase 2
Completed NCT03177759 - Living With Prostate Cancer (LPC)
Completed NCT01331083 - A Phase II Study of PX-866 in Patients With Recurrent or Metastatic Castration Resistant Prostate Cancer Phase 2
Recruiting NCT05540782 - A Study of Cognitive Health in Survivors of Prostate Cancer
Active, not recruiting NCT04742361 - Efficacy of [18F]PSMA-1007 PET/CT in Patients With Biochemial Recurrent Prostate Cancer Phase 3
Completed NCT04400656 - PROState Pathway Embedded Comparative Trial
Completed NCT02282644 - Individual Phenotype Analysis in Patients With Castration-Resistant Prostate Cancer With CellSearch® and Flow Cytometry N/A
Recruiting NCT06305832 - Salvage Radiotherapy Combined With Androgen Deprivation Therapy (ADT) With or Without Rezvilutamide in the Treatment of Biochemical Recurrence After Radical Prostatectomy for Prostate Cancer Phase 2
Recruiting NCT06037954 - A Study of Mental Health Care in People With Cancer N/A
Recruiting NCT05761093 - Patient and Physician Benefit/ Risk Preferences for Treatment of mPC in Hong Kong: a Discrete Choice Experiment
Completed NCT04838626 - Study of Diagnostic Performance of [18F]CTT1057 for PSMA-positive Tumors Detection Phase 2/Phase 3
Recruiting NCT03101176 - Multiparametric Ultrasound Imaging in Prostate Cancer N/A
Completed NCT03290417 - Correlative Analysis of the Genomics of Vitamin D and Omega-3 Fatty Acid Intake in Prostate Cancer N/A
Completed NCT00341939 - Retrospective Analysis of a Drug-Metabolizing Genotype in Cancer Patients and Correlation With Pharmacokinetic and Pharmacodynamics Data
Completed NCT01497925 - Ph 1 Trial of ADI-PEG 20 Plus Docetaxel in Solid Tumors With Emphasis on Prostate Cancer and Non-Small Cell Lung Cancer Phase 1
Recruiting NCT03679819 - Single-center Trial for the Validation of High-resolution Transrectal Ultrasound (Exact Imaging Scanner ExactVu) for the Detection of Prostate Cancer
Completed NCT03554317 - COMbination of Bipolar Androgen Therapy and Nivolumab Phase 2
Completed NCT03271502 - Effect of Anesthesia on Optic Nerve Sheath Diameter in Patients Undergoing Robot-assisted Laparoscopic Prostatectomy N/A